Weight loss pills instead of injections: what's genuinely available in the UK

You've looked at the pen and thought: not for me. Here's where that leaves you

The scenario is common. Someone researches GLP-1 weight-loss treatment, reads about the results, and then hits a wall: weekly self-injections feel like a step too far. For years the honest answer was that the only licensed weight-loss options in this drug class were subcutaneous pens. That changed on 11 June 2026, when the MHRA granted approval to Wegovy in tablet form (oral semaglutide co-formulated with an absorption enhancer) as the first GLP-1 medicine in tablet format licensed for weight management in the UK.

The tablet is taken once daily, first thing in the morning, on a completely empty stomach, with a small amount of plain water. You wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medicines. No fridge required. No needles. For anyone whose objection to the injection was practical rather than philosophical, that difference matters enormously. Our page on whether a weight-loss pill can replace the injection covers the licensing background in more detail if you want to go further on that specific question.

It is worth being clear about what has not changed. The medicine is still semaglutide, the same active ingredient as in the Wegovy pen. The clinical pathway (consultation, prescriber review, prescription) is identical. The MHRA approval means it has been assessed for safety and efficacy to the same standard as any other licensed UK medicine, and the NHS semaglutide page covers the side-effect profile that applies to both forms.

What the trial evidence says, and how the tablet and injection numbers compare

The phase-3 OASIS 4 trial randomised 307 adults with obesity or overweight alongside at least one weight-related condition, without diabetes, over 64 weeks. The result: an average weight reduction of around 13.6% on the tablet versus around 2.4% on placebo, both groups receiving lifestyle support. Among participants who adhered fully throughout, the average on the tablet reached roughly 17%. That figure is real but requires its context: it reflects the adherent subgroup, not the full trial population.

By comparison, the STEP 1 trial of the 2.4mg weekly semaglutide injection showed an average weight reduction of around 15% over 68 weeks, and the higher 7.2mg injection dose has since reported around 20.7% in further trials. Tirzepatide (Mounjaro), the dual-agonist weekly pen, produced average reductions of around 20-21% at its highest dose in the SURMOUNT-1 trial. For a fuller side-by-side look at those numbers, the pills versus injections comparison lays them out in one place.

The tablet, then, produces meaningful weight loss, but the injection, particularly at higher doses, currently shows larger average reductions in the trial data. Whether that gap matters for any individual depends on their starting weight, their health profile, how they tolerate the medicine, and what their prescriber recommends. It is not a straightforward swap where one is simply better; they are different tools assessed on different people over different timeframes.

The practical differences that might actually tip the decision

Efficacy figures are only part of what people weigh up. The injection pen arrives by tracked, next-working-day delivery in plain packaging (a small box, no branding visible) and lives in the fridge. The tablet needs neither. That single fact changes travel, routine and discretion in ways that matter to real people. Our page on weight loss tablets as an alternative to injections goes into more of the day-to-day practical detail.

The injection is administered once weekly, which means one conscious act, one injection-site decision, and six days of simply continuing. The tablet is daily, with the empty-stomach requirement each morning. Some people find a weekly event easier to build into a routine; others prefer the rhythm of a daily habit. Neither is objectively simpler, it depends on your life. For those still weighing it up, whether injections or pills work better explores how individual factors shape the answer.

Side effects follow a broadly similar pattern for both forms: nausea, changes in bowel habit, reduced appetite, and occasional headaches or fatigue, most noticeable when starting or moving to a higher dose, often settling within the first couple of weeks. The tablet trial recorded gastrointestinal effects in about 74% of participants on the active medicine, which was higher than the injection comparisons in separate trials, though direct head-to-head data between the tablet and injection is limited.

On cost, the tablet is a newer addition and private pricing is still settling. A broader look at how weight loss injection costs are structured gives useful context for how these medicines are priced generally in the UK private market. For a realistic view of the full cost picture, including what a legitimate private prescription includes, the guide to cheap weight loss injection claims is worth reading before making a decision on price alone.

What a prescriber actually looks at when you say you'd prefer a tablet

A prescriber does not simply hand over a tablet because you expressed a preference for it. They look at your BMI, your medical history, any existing conditions, your current medicines, and whether the tablet's licensed criteria match your situation. The Wegovy tablet is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition. Those are the same broad thresholds as the injection. But your prescriber may have clinical reasons to lean one way or the other, including whether you are already established on an injectable dose, in which case a conversation about moving across is a clinical decision in its own right.

The question of whether pills are as effective as injections is one our clinical team fields regularly, and the honest answer is: it depends on the dose, the person, and the duration. What is not in doubt is that both pathways require genuine clinical oversight. Our clinical team, including our lead prescriber, reviews every consultation personally before anything is dispensed. If you have further questions before starting, our FAQs cover many of the most common ones.

If you are ready to explore whether a tablet or injection suits your situation, speaking to our prescribers is the natural next step. Start your free consultation on the weight loss treatments page and a GPhC-registered prescriber will review your answers the same day.